The HemOnc Pulse Live at ASH: John DiPersio, MD, PhD, Discusses Challenges, Role of HSCT in AML
By Chadi Nabhan, MD, MBA, FACP, John DiPersio, MD, PhD - Last Updated: January 10, 2023John DiPersio, MD, PhD, stops by The HemOnc Pulse, from Blood Cancers Today and the Society of Hematologic Oncology, to talk about acute myeloid leukemia (AML) highlights from the 64th ASH Annual Meeting with host Chadi Nabhan, MD, MBA, FACP. Dr. DiPersio and Dr. Nabhan discussed menin inhibitors, bispecific antibodies, current challenges in treating AML, the role of allogeneic hematopoietic stem-cell transplant, and more.
Advertisement
Post Tags:AML ASH 22
Advertisement
Related Posts
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
A systemic review found that 21 of 90 randomized controlled trials for AML reported on patients' race and ethnicity.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.